The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ... progression-free survival in patients with chronic ...

Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.

Treatment sequencing with a covalent Bruton tyrosine kinase inhibitor (cBTKis) followed by a B-cell lymphoma-2 (BCL2) inhibitor and anti-CD20 monoclonal antibody (aCD20abs) was associated with better ...

The stem cells can come from a donor or be removed from the patient before chemotherapy. The type of T-cell lymphoma that someone is diagnosed with will determine the prognosis (outcomes). However, ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

1 While some patients present with an indolent form of the disease, mantle cell lymphoma generally has an aggressive disease course and a poor prognosis. 1 Ensuring optimal patient outcomes ...

Source: Getty Images Results from the AMPLIFY and BRUIN CLL-321 trials could support the approval of new drugs for chronic lymphocytic leukemia and small lymphocytic lymphoma, according to experts.

Tafasitamab (MOR-208, XmAb5574) is under development for the treatment of B cell malignancies including relapsed or refractory non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia ...

We present a case of SLL with a previously unreported complication demonstrating perniosis-like features involving the fingers and toes. The infiltration of the periungual areas with lymphoma ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.